As tumors rapidly develop, they outgrow their blood supply and the stores of nutrients and growth-stimulating metabolites they need to survive.
To satisfy their needs, cancer cells reprogram their metabolism, remodel their surroundings, recruit non-malignant cells and even provide aid to each other—engaging in “cross-talk” to help expand their population. Tumors use the same adaptive strategies to resist chemotherapy, targeted therapy and to suppress the immune system.
We are studying the metabolic and signaling pathways that support tumor growth metastasis, drug resistance and immune suppression. We make significant efforts to build dialogue with clinicians and physician scientists across the country and in neighboring institutions to ensure the translational and human relevance of our research. As our knowledge of the adaptive strategies tumors use to survive increases, so does the number of molecules and pathways we can potentially target for cancer treatment.
– Jorge Moscat, Ph.D., Program Director
Adipocyte p62/SQSTM1 Suppresses Tumorigenesis through Opposite Regulations of Metabolism in Adipose Tissue and Tumor.
Huang J, Duran A, Reina-Campos M, Valencia T, Castilla EA, Müller TD, Tschöp MH, Moscat J, Diaz-Meco MT
Cancer Cell 2018 Apr 9 ;33(4):770-784.e6
Ekanayake V, Nisan D, Ryzhov P, Yao Y, Marassi FM
Biophys J 2018 Aug 7 ;115(3):533-542
Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy.
Lundquist MR, Goncalves MD, Loughran RM, Possik E, Vijayaraghavan T, Yang A, Pauli C, Ravi A, Verma A, Yang Z, Johnson JL, Wong JCY, Ma Y, Hwang KS, Weinkove D, Divecha N, Asara JM, Elemento O, Rubin MA, Kimmelman AC, Pause A, Cantley LC, Emerling BM
Mol Cell 2018 May 3 ;70(3):531-544.e9
Reina-Campos M, Diaz-Meco MT, Moscat J
Cancer Cell 2019 Aug 14 ;
Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, Gulley JL, Lee JK, Diaz-Meco MT, Small EJ, Shen MM, Knudsen KE, Goodrich DW, Lotan TL, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson TC, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS
Clin Cancer Res 2019 Jul 30 ;
Bou-Nader M, Caruso S, Donne R, Celton-Morizur S, Calderaro J, Gentric G, Cadoux M, L'Hermitte A, Klein C, Guilbert T, Albuquerque M, Couchy G, Paradis V, Couty JP, Zucman-Rossi J, Desdouets C
Gut 2019 Apr 12 ;
Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer.
Reina-Campos M, Linares JF, Duran A, Cordes T, L'Hermitte A, Badur MG, Bhangoo MS, Thorson PK, Richards A, Rooslid T, Garcia-Olmo DC, Nam-Cha SY, Salinas-Sanchez AS, Eng K, Beltran H, Scott DA, Metallo CM, Moscat J, Diaz-Meco MT
Cancer Cell 2019 Mar 18 ;35(3):385-400.e9
Pimienta G, Heithoff DM, Rosa-Campos A, Tran M, Esko JD, Mahan MJ, Marth JD, Smith JW
Proteomics 2019 Mar ;19(5):e1800389
A Combination of Flow and Batch Mode Processes for the Efficient Preparation of mGlu<sub>2/3</sub> Receptor Negative Allosteric Modulators (NAMs).
Dhanya RP, Herath A, Sheffler DJ, Cosford NDP
Tetrahedron 2018 Jun 21 ;74(25):3165-3170